Navigation Links
New myeloma drug shows promise in early testing
Date:6/7/2010

ANN ARBOR, Mich. A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer.

A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism. The early stage trial combined elotuzumab with bortezomib, or Velcade, one of the novel chemotherapies approved to treat multiple myeloma, a cancer that arises in the plasma cells.

"Elotuzumab was found to work in synergy with bortezomib in a pre-clinical model, which served as the basis for this clinic trial. The regimen was well-tolerated, and many patients stayed on it for a long time," says Andrzej Jakubowiak, M.D., Ph.D., director of the Multiple Myeloma Program at the University of Michigan Comprehensive Cancer Center. Jakubowiak presented results of the study at the American Society of Clinical Oncology annual meeting.

The study looked at 28 patients with multiple myeloma that had relapsed or become unresponsive to treatment. Overall, 48 percent responded to the elotuzumab and bortezomib combination and patients' cancer progressed after an average 9.45 months. These numbers are better than in previous studies of patients with less advanced disease treated with bortezomib alone in which 38 percent responded to the treatment and cancer progressed after an average of 6.22 months.

"The study was not designed to evaluate statistical superiority of the combination of elotuzumab and Velcade, but it does appear to support our preclinical evidence that these two drugs work together," Jakubowiak says.

The researchers will next consider a study to compare the combination of elotuzumab and bortezomib against standard therapy to see if the combination achieves better results.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Page: 1

Related medicine news :

1. Drug shows positive responses, low side-effects in multiple myeloma
2. Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
3. Multiple myeloma patients experience high response rate with new 3-drug combination
4. Experimental targeted therapy shows early promise against medulloblastomas
5. Targeted Therapy Shows Promise Against Deadly Brain Cancer
6. Selenium shows no benefit in prevention of lung cancer
7. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
8. Spending time in nature makes people feel more alive, study shows
9. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
10. Prostate Cancer Vaccine Shows Few Side Effects
11. Brief Exercise Reduces Impact of Stress on Cell Aging, UCSF Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... closing of a growth round of funding led by Eastside Partners, with participation ... the company’s rapidly growing customer base and accelerate its technology and product roadmap. ...
(Date:4/29/2016)... ... ... Regenerative Medicine Solutions (RMS) scored 94.8124 out of 100 on Tampa ... for Tampa’s Best Places to Work. They were ranked in the Big Category, which ... our team,” says RMS Human Resources Manager Irene Miller. “We work hard to build ...
(Date:4/29/2016)... ... ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- Dr. Mickey S. ... are proud of the recent release of their 2014 in vitro fertilization success rates ... the latest verified data for 375 U.S. member clinics. *Preliminary data shows HRC/OC achieved ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. recently ... of probiotics, Petbiotics ™, as they fondly call them. As animal lovers, ... networking for their non-profit organizations. Animal rescues across the nation face huge hurdles ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... outsourced billing and coding services, and Deyta Analytics, recently announced the recipients of ... highest level of quality as measured from the caregiver’s point of view. The ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 2016 Tie-up with Government hospitals ... to save newborns   Fortis La Femme, ... in collaboration with Breast Milk Foundation (BMF), a non-profit organization ... Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes ... infants and should be available to babies deprived of mother,s ...
(Date:4/27/2016)... SAN FRANCISCO , April 27, 2016 /PRNewswire/ ... to reach over USD 2.14 billion by 2022, ... Research, Inc.       (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... key technological advancement affecting the efficiency and accuracy ... hence, the persistent demand for novel urinalysis instruments ...
(Date:4/26/2016)... US demand for infection prevention products ... annually to $27.6 billion in 2020.  Increasing pressures ... rates of healthcare-associated infections (HAIs) will boost revenues ... Although declining, the overall rate of certain HAIs ... by the CDC.  Recent statistics indicate that only ...
Breaking Medicine Technology: